IRF1 and colorectal cancer: In colorectal cancer and melanoma, knockout of METTL3 and METTL14 inhibits m6A modification, stabilizes STAT1 and IRF1 mRNA expression, and promotes IFNγ-Stat1-Irf1 signaling transduction through the synergistic effects of YTHDF2, which increases the expression of CD8+ T cells, and increases the secretion of IFN-γ, CXCL9 and CXCL10, enhances the response of pMMR-MSI-L to PD-1 treatment [159].